en · de · es · pt
tirzepatide-notes.peptides1126.com › News › Dual Incretin Receptor Agonism — Worked Examples

Dual Incretin Receptor Agonism — Worked Examples

By Editorial Desk · published 2025-08-29 · last reviewed 2025-10-06 · News

If you have been reading about GIP receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-10-06. Where a claim depends on a specific study, the study is described rather than over-claimed.

Dual Incretin Receptor Agonism

Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

储存处理与检测方法

纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息:前者反映疏水性杂质,后者反映聚集体,质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异,属于需要逐案验证的问题。

质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持,单次测定不足以判定批次的稳定性。实验室之间方法转移时,色谱柱品牌与梯度差异常导致保留时间漂移,因此方法验证十分必要。

Tirzepatide at a glance

PropertyValueNotes
Molecular classSynthetic peptideDual GIP/GLP-1 receptor agonist
Amino acid count39Contains non-natural residues
ModificationC20 fatty diacidAttached via linker; promotes albumin binding
Half-lifeApproximately 5 daysSupports once-weekly dosing
Primary routeSubcutaneous injectionNot for intravenous use

Tirzepatide Pharmacology and Development History

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Related pages on this site

Background And Receptor Pharmacology

Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Notes from published material

Afghanistan makes up almost two thirds of the land under illicit opium poppy cultivation in the world. The opiate trade originating in Afghanistan fuels the corruption throughout the country by funding the Taliban and their activities. This has been confirmed through drug seizures made by the CMF, who have concluded that the drugs originated from areas in Afghanistan controlled by the Taliban, by using a combination of the drug stamps found on the bags of heroin, and the isotope testing of the poppy gum. The UNODC estimated that in 2009 alone, the Taliban received 140-170 million USD from the opiate trade. This has also had social implications for the population, with an estimated 2 - 2.5 million people using drugs in Afghanistan alone.

Holick helped develop the first clinical assays for 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, determined how vitamin D3 is made in the skin from sun exposure, and established how season, time of day, skin pigmentation, sunscreen use, and latitude influenced this vital cutaneous process. He established that the skin was not only the organ responsible for making vitamin D3 but was also a target tissue for its active form, 1,25-dihydroxyvitamin D3. He determined the extremely inhibitory effects of 1,25-dihydroxyvitamin D3 on keratinocyte proliferation and the promoting effects on differentiation, and translated these seminal observations by demonstrating that the topical application of 1,25-dihydroxyvitamin D3 and several of its analogs were effective for the treatment of psoriasis. He demonstrated that macrophages and prostate cells have the enzymatic machinery to produce 1,25-dihydroxyvitamin D3, and established that the extrarenal production of 1,25-dihydroxyvitamin D3 may play a crucial role not only in cancer prevention but also in regulating the immune system. He developed a vitamin D absorption test and demonstrated that vitamin D was bioavailable in orange juice, leading to fortification of juice products in the United States. He also used the test to demonstrate the major cause of vitamin D deficiency in obesity is sequestration of vitamin D in the fat. He helped perform dose escalation studies establishing how much vitamin D is required to maintain blood levels of 25-hydroxyvitamin D in the sufficient range for adults.

== Examples == β-Amino acids with a wide variety of substituents exist. Named by analogy to the biological α-amino acids, the following have been found naturally: β-alanine, β-leucine, β-lysine, β-arginine, β-glutamate, β-glutamine, β-phenylalanine and β-tyrosine. Of these, β-alanine is found in mammals and incorporated in pantothenic acid, an essential nutrient. Aspartic acid is structurally a β-amino acids. Microcystins are a class of compounds containing a β-isoaspartyl (i.e. aspartic acid linked with its beta-carboxyl) residue.

Sources: en.wikipedia.org

Background from the literature

==== Collagen ==== Hydroxyproline is a major component of the protein collagen, comprising roughly 13.5% of mammalian collagen. Hydroxyproline and proline play key roles for collagen stability. They permit the sharp twisting of the collagen helix. In the canonical collagen Xaa-Yaa-Gly triad (where Xaa and Yaa are any amino acid), a proline occupying the Yaa position is hydroxylated to give a Xaa-Hyp-Gly sequence. This modification of the proline residue increases the stability of the collagen triple helix. It was initially proposed that the stabilization was due to water molecules forming a hydrogen bonding network linking the prolyl hydroxyl groups and the main-chain carbonyl groups. It was subsequently shown that the increase in stability is primarily through stereoelectronic effects and that hydration of the hydroxyproline residues provides little or no additional stability.

Woven bone is produced when osteoblasts produce osteoid rapidly, which occurs initially in all fetal bones, but is later replaced by more resilient lamellar bone. In adults, woven bone is created after fractures or in Paget's disease. Woven bone is weaker, with a smaller number of randomly oriented collagen fibers, but forms quickly; it is for this appearance of the fibrous matrix that the bone is termed woven. It is soon replaced by lamellar bone, which is highly organized in concentric sheets with a much lower proportion of osteocytes to surrounding tissue. Lamellar bone, which makes its first appearance in humans in the fetus during the third trimester, is stronger and filled with many collagen fibers parallel to other fibers in the same layer (these parallel columns are called osteons). In cross-section, the fibers run in opposite directions in alternating layers, much like in plywood, assisting in the bone's ability to resist torsion forces. After a fracture, woven bone forms initially and is gradually replaced by lamellar bone during a process known as "bony substitution". Compared to woven bone, lamellar bone formation takes place more slowly. The orderly deposition of collagen fibers restricts the formation of osteoid to about 1 to 2 μm per day. Lamellar bone also requires a relatively flat surface to lay the collagen fibers in parallel or concentric layers.

The low demand makes working mines for extraction of thorium alone not profitable, and it is almost always extracted with the rare earths, which themselves may be by-products of production of other minerals. The current reliance on monazite for production is due to thorium being largely produced as a by-product; other sources such as thorite contain more thorium and could easily be used for production if demand rose. Present knowledge of the distribution of thorium resources is poor, as low demand has led to exploration efforts being relatively minor. In 2014, world production of the monazite concentrate, from which thorium would be extracted, was 2,700 tonnes. The common production route of thorium constitutes concentration of thorium minerals; extraction of thorium from the concentrate; purification of thorium; and (optionally) conversion to compounds, such as thorium dioxide.

== External links == "Vildagliptin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 8 June 2020. "Metformin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 17 May 2016.

Sources: en.wikipedia.org

Frequently asked questions

What receptors does tirzepatide target?

It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.

How is tirzepatide administered?

It is given as a subcutaneous injection. Its long half-life supports weekly dosing.

Is tirzepatide a natural peptide?

No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.

固体粉末应如何存放?

建议在低温、避光、干燥环境中密封保存,常见条件为 2 至 8 摄氏度,长期存放可置于更低温度。应避免反复冻融,并尽量减少容器开启次数。

Network